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native dementia identification strategy. The approaches of screening and case-finding are often
confused, with uncertainty about what case-finding should involve and under what circumstances
it is appropriate. We propose a formal definition of dementia case-finding with a clear distinction
from screening. We critically examine case-finding policy and practice and propose evidence require-
ments for implementation in clinical practice. Finally, we present a case-finding pathway and discuss
the available evidence for best practice at each stage, with recommendations for research and prac-
tice. In conclusion, dementia case-finding is a promising strategy but currently not appropriate due to
the substantial gaps in the evidence base for several components of this approach.
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1.1. The case for early diagnosis
Balancing the potential harms and benefits of diagnosing
dementia is a contentious issue as there are no disease-
modifying treatments for dementia, and a formal diagnosis
may not benefit everyone [1]. A recent systematic review
found that most people both with and without cognitive
impairment, would prefer to know if they had dementia to
allow greater autonomy in decision-making for future care
and legal issues and time to prepare for challenges [2]. These
perceived benefits are contingent on receipt of a timely diag-
nosis, allowing earlier access to resources and services such
as symptom management and psychosocial interventions. A
missed or delayed diagnosis limits these opportunities and
can compromise safety [3]. Economic modeling also sug-
gests that earlier diagnosis is likely to be cost effective by
increasing quality of life and delaying institutionalizationthor. Tel./fax: 144 (0) 1392 726018.
vid.llewellyn@exeter.ac.uk
/j.trci.2018.04.011
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).[4]. Earlier identification of dementia is an international
health priority [5,6] and an important element of various
National Dementia Strategies [7].1.2. Challenges of identifying dementia
Many people with dementia never receive a diagnosis,
and most cases in lower income countries are likely to be un-
diagnosed [5]. Dementia is challenging to diagnose, partic-
ularly in the early stages. Many symptoms overlap with
conditions such as depression, delirium, and functional
problems, and patients with dementia often do not report
subjective cognitive complaints to a physician [8]. There is
currently no single, accurate test to identify dementia, and
family physicians’ judgments of dementia status are often
inaccurate [9]. Barriers to the diagnosis of dementia
commonly identified by physicians include lack of knowl-
edge and confidence, inadequate tools and protocols, con-
cerns regarding potential harms of diagnosis, risk of
misclassification, and difficulty of communicating a diag-
nosis [10]. Population screening for dementia is currentlyimer’s Association. This is an open access article under the CC BY-NC-ND
Box 1 Examples of screening and case-finding definitions
Definition of Screening
 “A public health service in which members of a defined population, who do not necessarily perceive they are at risk of,
or are already affected by, a disease or its complications, are asked a question or offered a test to identify those indi-
viduals who are more likely to be helped than harmed by further tests or treatment to reduce the risk of disease or its
complications” [16].
Descriptions of case-finding
 “That form of screening of which the main objective is to detect disease and bring patients to treatment, in contrast to
epidemiological surveys” [17].
 “A systematic or opportunistic process that identifies individuals (e.g., people with COPD) from a larger population for
a specific purpose, for example, Flu vaccination” [18].
Description of case-finding used within the context of dementia identification:
 “Identification of possible/probable dementia. targeted on those with a higher prior probability of having the disease”
[14].
 “Assessment of a subgroup of individuals identified on the basis of known risk factors (e.g., subjective cognitive con-
cerns or family history of dementia) to be carried out by physicians and other health professionals” [15].
 “Case-finding is aimed at individual patients who in the clinical opinion of the GP may benefit from a dementia assess-
ment” [19].
J.M. Ranson et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 288-296 289not recommended by evidence scrutiny bodies for national
screening programs in the UK and United States due to
insufficient evidence of the potential benefits and harms
[11,12]. Instead, clinical guidelines recommend case-
finding in clinical practice, where clinicians offer a dementia
investigation to patients attending consultations for other
reasons [13–15].
In this review, we examine the concept of case-finding
and how it differs from screening. We provide a formal defi-
nition of dementia case-finding and consider under what
conditions it is appropriate. Finally, we outline a dementia
case-finding pathway and the evidence for best practice at
each stage.2. What is dementia case-finding? A conceptual
framework
Missing from the literature is an agreed definition of
“case-finding”. There is much ambiguity around what it
means, particularly with respect to how it differs from
screening (see Box 1). An editorial by Wald and Morris
[20] called for the term “case-finding” to be abandoned
due to concern that the term may be used to justify a
screening initiative while avoiding the need for an evi-
denced, evaluated program with a demonstrated benefit.
The dementia identification strategies of screening and
case-finding continue to be confused, with direct impact
on patients and clinicians due to the lack of evidence accom-
panying implementation, and McCartney has noted the need
for a formal definition of case-finding [21].2.1. A formal definition of dementia case-finding
To improve the clarity of what dementia case-finding is
and under what conditions it may be appropriate, we propose
the following definition:“An offer of a brief, opportunistic investigation to identify
possible signs or symptoms of dementia, initiated by a
clinician during consultation with a patient at high risk
of dementia on the basis of clinical judgment that an
initial dementia enquiry is appropriate and is likely to
benefit the patient”.This definition encompasses the following four features:
Purpose: To identify a possible case of unrecognized de-
mentia for potential benefit to the patient.
Context: The decision to offer dementia case-finding is
made during a clinical consultation with a patient, where
the clinician has no preexisting concern of possible signs
of dementia, and the patient has not raised any self-
reported cognitive complaints. Unlike a screening pro-
gram, the decision to offer case-finding relies on a
patient-centered clinical judgment of appropriateness
and potential benefit for a given patient.
Target group: A patient offered case-finding should meet
predefined criteria for membership in an evidence-based
high-risk group.
Process: Case-finding is offered and not imposed on the
patient. The patient should give prior consent to any
case-finding investigations or tests. The definition inten-
tionally excludes the method of investigation, which
should be chosen in accordance with the best evidence
and guidance available at the time. The process of
case-finding is not synonymous with a brief cognitive
assessment, although this may form part of the case-
finding process. Identification of a concern at this stage
would warrant further investigation or referral to
specialist services.
Adoption of this definition of dementia case-finding
would have implications for patients, clinicians, health-
care providers and systems, and political bodies. The term
would no longer serve as a vague description to justify
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Fig. 1. Potential routes to the identification of dementia.
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an evidence-based protocol for the identification of patients
for whom the offer of case-finding is appropriate. This pro-
tects patients from potentially inappropriate or ill-advised
policies and procedures, supports clinical decision-making,
and provides a clear basis for the development and assess-
ment of evidence-based practice.2.2. Differentiating the routes to the identification of
dementia
Case-finding is one of four potential routes to a dementia
diagnosis (see Fig. 1). These are as follows: (a) clinical
recognition of signs or symptoms, (b) investigation of sub-
jective concerns (reported by the patient or an informant),
(c) case-finding in clinical practice, and (d) population
screening. The World Health Organization [14] notes the
importance of distinguishing between dementia case-
finding and screening. They emphasize that the difference
is that case-finding is conducted by targeting high-risk
groups. However, all population-screening programs are
restricted to specific groups, for example, stratifying by
age. Risk stratification therefore does not distinguish be-
tween screening and case-finding. Indeed, the UK National
Screening Committee (NSC) [16] highlights the importance
of allowing screening programs to target high-risk groups.
Other efforts to distinguish between these related ap-
proaches have emphasized that case-finding is conducted
opportunistically with patients who have initiated contact
with the clinician by attending for another reason. In
contrast, if patients are invited to attend for screening, this
carries an implied benefit of that screening [22,23].
However, this does not provide a sufficient distinction, as
screening practices may be conducted opportunistically,
for example, screening for hypertension by checking blood
pressure during outpatient visits [24]. Moreover, we agree
with the position taken by Wald and Morris [25]; the fact
that the investigation is conducted opportunistically when
the patient has attended for an unrelated matter should not
impinge on the requirement for evidenced potential benefit.
Our distinction between screening and case-finding is
focused on the clinical context itself; screening programs
specify the offer of investigation to all individuals in a
predefined group. In contrast, case-finding involvespatient-centered clinical judgment to assess whether offer-
ing the investigation is appropriate and of potential benefit
in the case of a specific patient. The ethical implication of
clinical decision-making in the initiation of case-finding is
a subtle but crucial difference between the related ap-
proaches of screening and case-finding. This is of core
clinical importance with implications for both patients
and clinicians. In Table 1, we provide a more detailed
comparison according to our proposed definition of de-
mentia case-finding.3. Dementia identification policy and practice
To illustrate the subtle but important difference between
case-finding and screening in clinical practice, we review
two recent examples of government initiatives to improve
the identification of dementia.3.1. Case study 1: United States—detection of cognitive
impairment in the Annual Wellness Visit
Medicare is a federal health insurance program for US res-
idents aged 65 and older, in addition to certain younger people
withdisabilities andpeoplewithend-stage renal disease. Since
2011, the Affordable Care Act has required the provision of a
Medicare Annual Wellness Visit to detect any cognitive
impairment, including dementia. This involves an assessment
of cognitive function by physician observation and interview
with the patient and a knowledgeable informant about subjec-
tive cognitive impairment [26].Tooperationalize the detection
of cognitive impairment during the Annual Wellness Visit, an
expert workgroup, convened by the Alzheimer’s Association,
produced the “Medicare Annual Wellness Visit algorithm for
assessment of cognition” which recommends a referral or full
dementia evaluation for potential cases [27]. The algorithm
recommends a structured cognitive assessment if the clinician,
patient, or informant report possible signs or symptoms of de-
mentia. It also recommends an assessment if there is no infor-
mant available, even if no concerns are held by the patient or
the clinician.
There is a lack of evidence for the impact or acceptability of
this approach, and the take-up by eligible beneficiaries has been
low. In 2014, the visit was received by less than 16% of all
eligible beneficiaries, with regional rates ranging from 3% to
Table 1
Comparison of screening and case-finding dementia identification strategies
Strategy characteristics Screening Case-finding
Process An initial investigation such as a question or simple test, with a
positive indication followed by an offer of further
investigation.
Identical to screening.
Type of
initiative
May be systematic (e.g., target patients are invited to attend a
screening appointment) or opportunistic (e.g., an offer of a
test when patients attend a consultation).
Opportunistic and based on clinical judgment of potential
benefit during a consultation.
Scale of
initiative
Invitations for screening may be large scale (e.g., national
programs) or small scale (e.g., specific health trusts with low
diagnostic rates or diseases in certain geographical areas).
Forms part of clinical practice, although clinicians may be
encouraged to conduct case-finding by national or regional
policy in response to low diagnostic rates.
Target
groups
May be targeted on a broad population (e.g., women aged 25–60)
or more narrowly defined high-risk groups (e.g., those with
specificmedical conditions). An important element is that it is
offered to nonsymptomatic individuals.
Targeted on selected high-risk groups on a case-by-case basis
according to the clinician’s judgment of potential benefit.
Evidence
requirements
Formal assessment of a screening program proposal against
criteria regarding knowledge of the condition and potential
benefits and harms of screening to the target group as a whole.
No formal evidence requirements at present.
Who initiates
the investigation
The body responsible for screening program implementation. The clinician, in making a decision that it may benefit a specific
patient.
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this initiative as an example of screening rather than case-
finding, as it assumes broad suitability without patient-
centered clinical judgment of potential benefit from the assess-
ment.3.2. Case study 2: England—incentivized detection of
dementia in the National Health Service
The Department of Health is responsible for policy and
funding of health and care in England. In recent years, it
introduced two separate financial incentive schemes,
encouraging clinicians to identify dementia during routine
clinical practice in primary care [29] and hospital settings
[30]. Different “at-risk” criteria were defined for each setting
(Box 2), although clinicians were required to ask the same
question to identify subjective cognitive concern;Bo
Ri“Have you/has [the patient] beenmore forgetful in the past
12 months, to the extent that it has significantly affected
your/their daily life? (Ask patient/relative/carer)”.x 2 Department of Health “at-risk” criteria for dementia
sk criteria for use in primary care [29].
 Aged 60 years or older with cardiovascular disease, stroke
 Aged more than 60 years and have a “high risk” of cardio
consumption, or obesity
 Aged more than 60 years with a COPD diagnosis
 Aged 40 years or older with Down’s syndrome
 Aged 50 years or older with learning disabilities
 Long-term neurological conditions that have a known neuro
isk criteria for use in hospitals [30].
 Over 75s who are the subject of an emergency admission t
nosed with dementia.In the absence of an informant, further investigation
was not recommended if the patient responded negatively.
Therefore, this relies more heavily on the patient’s subjec-
tive report than in the Annual Wellness Visit. The classi-
fication accuracy of this approach is unknown, but use of
subjective memory complaints has been highlighted as
inappropriate for dementia case-finding [8]. Both the
risk-group criteria and the subjective cognition question
were developed by clinical consensus, and neither has
been validated empirically. In addition, there is no alterna-
tive question provided for use with people with learning
difficulties despite learning difficulty being a risk factor.
The primary care scheme specification stated that the
initial dementia enquiry was to be conducted only if the clini-
cian believed it to be clinically appropriate and of potential
benefit to the patient. In contrast to the AnnualWellness Visit,
we regard this to be an example of case-finding, as it requires
a patient-centered evaluation ofwhether a dementia investiga-
tionmay be appropriate for a particular individual. The incen-
tives were based solely on the proportion of high-risk patients, peripheral vascular disease, or diabetes
vascular disease, for instance because of smoking, alcohol
degenerative element, for example, Parkinson’s disease.R-
o hospital or community services and are not already diag-
Table 2
Suggested dementia case-finding evidence requirements
Proposed criteria Currently met?
The condition
1. The condition should be an important health problem. Yes
2. The epidemiology and natural history of the condition, including development from latent to declared disease, should be
adequately understood, and there should be a detectable risk factor, disease marker, latent period, or early symptomatic
stage.
No
3. All the cost-effective primary prevention interventions should have been implemented as far as practicable. Difficult to assess
The test
4. There should be a simple, safe, precise, and validated case-finding test. The distribution of test values in the target population
should be known and a suitable cutoff level defined and agreed.
Partially met, awaiting
clarification of optimal
cutoff levels.
5. The test should be acceptable to the population. No
6. There should be an agreed policy on the further diagnostic investigation of individuals with a positive test result and on the
choices available to those individuals.
Yes
The treatment
7. There should be an effective treatment or intervention for patients identified through early detection, with evidence of early
treatment leading to better outcomes than late treatment.
No
8. There should be agreed evidence-based policies covering which individuals should be offered treatment and the appropriate
treatment to be offered.
Yes
9. Clinical management of the condition and patient outcomes should be optimized in all health-care providers before
participation in a case-finding program.
Not possible to assess
The case-finding program
10. There should be evidence from high-quality randomized controlled trials that the case-finding program is effective in
reducing mortality or morbidity.
No
11. There should be evidence that the complete case-finding program (test, diagnostic procedures, and treatment/intervention)
is clinically, socially, and ethically acceptable to health professionals and the public.
No
12. The benefit from the case-finding program should outweigh the physical and psychological harm (caused by the test,
diagnostic procedures, and treatment).
No
13. All other options for managing the condition should have been considered (e.g., improving treatment, providing other
services), to ensure that nomore cost-effective intervention could be introduced or current interventions increased within the
resources available.
No
14. There should be evidence that clinicians can assess the potential benefits of case-finding. No
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received much criticism. Concerns were raised regarding
the lack of evidence and harms of false positives, including
impact on patients and overload on memory services, with
suspicion that this was a dementia screening initiative being
implemented under the guise of case-finding in the absence
of evidence [21,31–33]. The scheme was dropped in 2016.
A separate scheme for hospital settings in England was
also introduced as a “case-finding” strategy, although we
suggest this is better described as an example of screening.
It was applied to all unplanned (emergency) admissions of
inpatients aged 75 years and older, with no further consider-
ation of potential benefit to individual patients. Affirmative
responses to the subjective cognition question were followed
by the Abbreviated Mental Test Score. This practice has
since become a mandatory component in the standard Gen-
eral Medical Services contract [34], and the CASe finding in
hospitals - impacts on CAre for people with DEmentia
(CASCADE) study [35] is currently investigating the effec-
tiveness of this policy and its impact on patients. Taken
together, these examples demonstrate the subtle but impor-
tant differences in the approaches to dementia identification
in policy and clinical practice.4. Is case-finding currently appropriate for dementia
identification?
Case-finding for dementia offers the potential to identify
more people for whom a diagnosis may otherwise be missed
or delayed. However, we must be cautious to ensure that the
potential risk of harm both from false negative and positive
diagnoses is minimized. There are currently no existing ev-
idence requirements against which case-finding initiatives
are assessed, and harm may be caused by inappropriate or
ineffective case-finding strategies. Therefore, we reviewed
the criteria for assessing evidence for screening proposals
and suggest that they also apply to case-finding. We used
the UK NSC criteria, which provide broad coverage of the
various screening criteria items used internationally to
make recommendations regarding population screening pro-
posals [36]. The NSC is also one of only two bodies that
require knowledge of the distribution of test values in the
target population, with agreed cutoff levels. This is particu-
larly relevant to the assessment of cognition.
Table 2 shows our proposed case-finding evidence criteria,
and whether each criterion is currently met. This is based on
the most recent appraisal against the NSC criteria, with an
Fig. 2. Dementia case-finding pathway.
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tial benefit to a given patient. We suggest that case-finding, as
defined in this review, is a promising dementia identification
strategy and would be appropriate under these conditions.
However, according to the available evidence, not all of these
criteria are currently met. A recent systematic review found
that dementia screening may not be acceptable to eitherpatients or clinicians [37]. Several of the barriers to acceptance
related to the clinical context (role of the clinician, clinical
communication, benefit, and the patient’s existing health, life-
style, and comorbidities). We therefore suggest that case-
finding may be more acceptable than screening, due to the
role of clinical judgment in offering case-finding, with
patient-focused consideration of potential benefit.
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like?
There is no agreed best practice for dementia case-
finding, and there is inconsistency in clinical guideline rec-
ommendations for the initial identification of possible
cases. The dementia case-finding pathway in Fig. 2 illus-
trates the five stages in the case-finding process that require
consideration. We review the quality of evidence for each
stage in the process and recommend further research to
address the evidence gaps. This could support the develop-
ment of an evidence-based case-finding protocol for
dementia.5.1. Stage one: Identify high-risk groups
To which individuals should case-finding be offered?
Various high-risk groups have been proposed, for which
the evidence base is unclear [15,29,34]. We suggest the
use of population-based cohort studies to inform the devel-
opment of clinical guidelines, by identifying patient groups
and combinations of patient characteristics which are
strongly and consistently associated with dementia.5.2. Stage two: Determine which patients are likely to
benefit from case-finding
There is a lack of literature on how clinicians can effec-
tively determine whether a given patient may benefit from
dementia enquiry. What comprises benefit for a patient? Es-
tablished screening criteria focuses on reducing mortality
and morbidity, although in the case of dementia, this needs
to incorporate improvement in quality of life in addition to
symptom management. For example, Olde Rikkert et al.
[38] suggest assessing cognition only in patients who report
a decline in well-being, on the basis that these individuals are
likely to have the greatest scope for improvement. There is
currently no evidence to suggest whether this approach
would be effective or acceptable to patients and clinicians.
It is important to note that potential benefits, such as
improved management and treatment resulting from case-
finding, also extend beyond the patient; families and carers
may benefit from support services where they are available,
and health service providers and payers may benefit
economically from reduction in avoidable crises and admis-
sions, particularly in areas where undiagnosed dementia is a
priority. Further work in this area should focus on identi-
fying which patient characteristics, case-finding strategies,
and clinical contexts are associated with enhanced patient
outcomes to support clinical decision-making.5.3. Stage three: Obtain informed consent for cognitive
investigation
Screening-appraisal bodies emphasize that patients should
decide whether to engage in screening according to the risks
and benefits to them as an individual. This ethical frameworkshould apply equally to case-finding, allowing patients to
make an informed choice of whether to accept an offer of
case-finding. Agreement should therefore be established
from the very beginning of any case-finding process, and there
is a need for an agreed procedure to facilitate access to case-
finding that is acceptable to both patients and clinicians.5.4. Stage four: Initial dementia enquiry
A single question used to identify those most likely to have
dementia would have the advantage of avoiding unnecessary
cognitive assessment. However, despite the tempting brevity
of single-item case-finding questions, their usage is inappro-
priate unless validated in the relevant population and clinical
setting, are acceptable to patients and clinicians, and offer a
reasonable balance of sensitivity and specificity for a partic-
ular clinical context. Questions measuring subjective cogni-
tion are particularly problematic; despite subjective
cognitive complaints being associated with dementia [39],
they are common in older people bothwith andwithout objec-
tive cognitive deficits, and most people with dementia do not
report memory problems when asked [40]. The proportion of
cases missed by this approach is high [8], so the use of a
patient-reported subjective cognition question is not currently
suitable for case-finding for dementia in a clinical setting.
Little research has evaluated case-finding questions for de-
mentia. Lessons may be learned from better-studied areas of
psychiatric case-finding. For example, incorporating an addi-
tional question depending on the patient’s responses has
shown to be successful in diagnostic accuracy studies for
case-finding questions used in depression [41]. This approach
has been found to be acceptable to patients [42]. In contrast,
informant-reported subjective cognition may be a more reli-
able indication of dementia status. In a nationally representa-
tive population-based study, an informant-reported single
question adequately discriminated between older adults
with and without dementia, outperforming the overall accu-
racy of the Informant Questionnaire on Cognitive Decline
in the Elderly (IQCODE), a validated informant questionnaire
[43]. A recent test-accuracy pilot study assessing the diag-
nostic properties of an informant-rated single-item case-
finding question for use in hospital settings also indicates
that this approach may be suitable for dementia case-
finding [44]. This used a five-point Likert scale response to
the question “How has your relative/friend’s memory
changed over the past 5 years (up to just before their current
illness)?” Any deterioration indicated cognitive impairment,
and this question performed well compared with the IQ-
CODE. An informant-reported single question such as this
may be useful, before the offer of cognitive assessment, to
identify individuals for whom a cognitive assessment is suit-
able while reducing unnecessary testing.
These findings are encouraging, but the evidence is not
currently sufficient to enable recommendation of a single
question to form part of dementia case-finding. Validation
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settings against a formal dementia diagnosis is required.
5.5. Stage five: Conduct a brief cognitive assessment
A recent systematic review of dementia practice guidelines
found general agreement on the recommendation of using
standardized brief cognitive assessment although there was
variation in the specific tools recommended, including
Mini-Mental State Examination, General Practitioner Assess-
ment of Cognition, and the Montreal Cognitive Assessment
amongst several others [45]. Identification of the most appro-
priate cognitive assessment depends on the setting in which it
will be used, for example, in primary or secondary care.
Some brief cognitive assessments are validated in the
target clinical settings; though it should be noted that using
a cognitive assessment in combination with a subjective
cognition question requires revalidation of the procedure as
a whole, and within the intended high-risk patient groups. Pa-
tient groups and context of usagemay affect the diagnostic ac-
curacy of the assessment. For example, if the assessment is
conducted only following a report of subjective cognitive
complaint, then the assessment is required to not only identify
dementia cases from non-cases but also specifically distin-
guish dementia from other sources of cognitive complaints
or concerns. The outcome of this stagewould be further inves-
tigation, reassurance, or a scheduled follow-up.6. Conclusions
The distinction between screening and case-finding is subtle
but important, with direct relevance to patients and clinicians.
Our definition of case-finding differentiates this practice from
screening. Case-finding initiatives should be individualized,
patient-focused, and subject to evidence requirements.
Evidence-based case-finding is a promising strategy to improve
diagnostic rates and increase the detection of cases. However,
we do not currently recommend the implementation of demen-
tia case-finding in clinical practice because the proposed evi-
dence requirements for this are not yet met. We have
identified the gaps in the evidence at each stage of the case-
finding process, and specific areas requiring further research
to inform evidence-based practice. They include criteria for tar-
geting high-risk groups, identification of those likely to benefit
fromcase-finding, and validation of an effective, acceptable de-
mentia case-finding question or initial enquiry.
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1. Systematic review: We reviewed the literature of
case-finding in clinical practice as a strategy for the
identification of dementia.
2. Interpretation: We examine the ambiguous concept
of case-finding and highlight the lack of evidence re-
quirements for public health strategies introduced
under this term. We propose a formal definition of
dementia case-finding with suggested evidence re-
quirements, and provide a case-finding pathway to
guide policy and clinical practice. This has the poten-
tial to inform appropriate and evidence-based de-
mentia identification strategies.
3. Future directions: Only when the proposed evidence
requirements are met would dementia case-finding in
clinical practice be recommended. Currently it re-
mains unclear whether patients may benefit from
case-finding, and whether clinicians can assess po-
tential benefit. Identification of appropriate criteria
for targeting high risk groups requires investigation
of patient and clinical characteristics associated
with dementia status in population-based cohorts.References
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